Related Experiment Video
Updated: May 22, 2026
Isolation of Region-specific Microglia from One Adult Mouse Brain Hemisphere for Deep Single-cell RNA Sequencing
Published on: December 3, 2019
Single-cell Dissection of Microglial Heterogeneity Reveals Subtype-driven Immune-metabolic Crosstalk in Major
Qingqing Li1, Yunfeng Wang2, Le Ma2
1Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, Tongji University School of Medicine, Shanghai 200124, China.
Introduction:
Major Depressive Disorder (MDD) is linked to excitation-inhibition imbalance in prefrontal cortex (PFC) neural circuits, whose formation relies on communication between neurons and microglia. However, the mechanisms underlying selective crosstalk between microglial subtypes and distinct inhibitory neuronal subtypes remain unclear.
Methods:
Single-nucleus RNA-seq data from the dorsolateral PFC (17 controls, 17 MDD) were retrieved from GEO. Microglia subsets and their interactions with GABAergic neurons were analyzed via standard single-cell pipelines. Predictive models were prioritized using 69 machine learning models, followed by Mendelian randomization to infer causality between microglial signatures and MDD.
Results:
Three microglial subtypes (MG_1-MG_3) with distinct signature genes were identified; dysregulation in microglia-GABAergic neuron crosstalk included impaired anti-inflammatory signalling (GAS6 in PVALB+ neuron-MG_2/MG_3; VIPR1 in VIP+ neuron-MG_2; CRHR2 in MG_2-LAMP5+/VIP+ neurons) and hyperactivation of pro-inflammatory pathways (TAC in LAMP5+ neuron-MG_3; VISFATIN in all neuron-MG_2).
Discussion:
MG_1 was defined as a transitional modulator-like functional phenotype, MG_2 as a pathogenic driver-like functional phenotype, and MG_3 as a damage executor-like functional phenotype. These functionally differentiated subsets formed a selective bidirectional crosstalk network with GABAergic neurons-targeting this network could directly modulate GABAergic function, potentially exerting antidepressant effects. Specific intervention strategies could focus on key pathways, including GAS6-TAM and VIP-VIPR1, TAC, and VISFATIN.
Conclusion:
Our deciphering of ligand-receptor-mediated crosstalk between microglial and GA-BAergic subtypes offers novel insights and potential targets for developing targeted cellular therapies for MDD.
Insights
Researchers identified three microglial subtypes in the prefrontal cortex and their crosstalk with GABAergic neurons in Major Depressive Disorder (MDD). Targeting these pathways may offer new antidepressant therapies.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Major Depressive Disorder (MDD) is associated with prefrontal cortex (PFC) neural circuit imbalances.
- Microglia-neuron communication is crucial for circuit development, but specific crosstalk mechanisms remain unclear.
Purpose of the Study:
- To investigate the crosstalk between microglial subtypes and GABAergic neurons in the PFC of individuals with MDD.
- To identify potential therapeutic targets for MDD based on microglial-neuronal interactions.
Main Methods:
- Single-nucleus RNA sequencing data from PFC of controls and MDD patients were analyzed.
- Microglia subsets and their interactions with GABAergic neurons were identified using computational pipelines.
- Machine learning and Mendelian randomization were employed to infer causality.
Main Results:
- Three distinct microglial subtypes (MG_1-MG_3) were identified.
- Dysregulated crosstalk involved impaired anti-inflammatory signaling (e.g., GAS6, VIPR1) and hyperactivated pro-inflammatory pathways (e.g., TAC, VISFATIN).
- Specific interactions were observed between microglial subtypes and distinct GABAergic neuron populations (PVALB+, VIP+, LAMP5+).
Conclusions:
- MG_1 acts as a transitional modulator, MG_2 as a pathogenic driver, and MG_3 as a damage executor.
- Targeting the identified microglial-GABAergic neuron crosstalk network could modulate GABAergic function and exert antidepressant effects.
- Key pathways like GAS6-TAM and VIP-VIPR1 present potential targets for MDD therapies.
